Parkside Financial Bank & Trust Has $124,000 Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Parkside Financial Bank & Trust increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 306.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,356 shares of the medical equipment provider’s stock after purchasing an additional 1,022 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Zimmer Biomet were worth $124,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ZBH. Ameriprise Financial Inc. boosted its holdings in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after acquiring an additional 1,488,918 shares in the last quarter. Nuveen LLC acquired a new position in Zimmer Biomet in the 1st quarter worth approximately $155,891,000. Alyeska Investment Group L.P. purchased a new position in Zimmer Biomet during the 1st quarter worth approximately $101,294,000. Finally, Dodge & Cox raised its stake in Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after purchasing an additional 446,018 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Canaccord Genuity Group decreased their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Evercore ISI lowered their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. BTIG Research dropped their target price on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $109.00.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Up 0.0%

Shares of Zimmer Biomet stock opened at $88.53 on Tuesday. The firm has a market cap of $17.55 billion, a price-to-earnings ratio of 21.54, a P/E/G ratio of 2.29 and a beta of 0.67. The stock has a 50-day simple moving average of $99.79 and a 200-day simple moving average of $97.38. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.